Based on the Mediwound Ltd stock forecast from 3 analysts, the average analyst target price for Mediwound Ltd is USD 27.33 over the next 12 months. Mediwound Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Mediwound Ltd is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Mediwound Ltd’s stock price was USD 17.45. Mediwound Ltd’s stock price has changed by +3.99% over the past week, -0.17% over the past month and +103.86% over the last year.
No recent analyst target price found for Mediwound Ltd
No recent average analyst rating found for Mediwound Ltd
Company Overview Mediwound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel. Read Less
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the re...Read More
Frequently Asked Questions About Mediwound Ltd (MDWD) Stock
Based on ratings from 3 analysts Mediwound Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on MDWD's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for MDWD is USD 27.33 over the next 12 months. The maximum analyst target price is USD 30 while the minimum anlayst target price is USD 25.
MDWD stock's Price/Earning ratio is 27.07.
Our analysis grades MDWD stock's Price / Earning ratio at F. This means that MDWD stock's Price/Earning ratio is above 77% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this MDWD may be a overvalued for its sector.
The last closing price of MDWD's stock was USD 17.45.
The most recent market capitalization for MDWD is USD 0.17B.
Based on targets from 3 analysts, the average taret price for MDWD is projected at USD 27.33 over the next 12 months.
This means that MDWD's stock price may go up by +56.64% over the next 12 months.
We can't find any ETFs which contains Mediwound Ltd's stock.
As per our most recent records Mediwound Ltd has 100 Employees.
Mediwound Ltd's registered address is 42 Hayarkon Street, Yavne, Israel, 8122745.
You can get more information about it from Mediwound Ltd's website at https://www.mediwound.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Mediwound Ltd (MDWD) Stock
Based on ratings from 3 analysts Mediwound Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on MDWD's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for MDWD is USD 27.33 over the next 12 months. The maximum analyst target price is USD 30 while the minimum anlayst target price is USD 25.
MDWD stock's Price/Earning ratio is 27.07.
Our analysis grades MDWD stock's Price / Earning ratio at F. This means that MDWD stock's Price/Earning ratio is above 77% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this MDWD may be a overvalued for its sector.
The last closing price of MDWD's stock was USD 17.45.
The most recent market capitalization for MDWD is USD 0.17B.
Based on targets from 3 analysts, the average taret price for MDWD is projected at USD 27.33 over the next 12 months.
This means that MDWD's stock price may go up by +56.64% over the next 12 months.
We can't find any ETFs which contains Mediwound Ltd's stock.
As per our most recent records Mediwound Ltd has 100 Employees.
Mediwound Ltd's registered address is 42 Hayarkon Street, Yavne, Israel, 8122745.
You can get more information about it from Mediwound Ltd's website at https://www.mediwound.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for MDWD !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
